Latest market headlines for MOREPENLAB on Terminal.
27-Oct-2026 13:47:26
• CDMO Revenue: Surged to ₹253 Cr in Q2 FY27 from ₹58 Cr in Q1 FY27; H1 revenue reached ₹311 Cr • Global CDMO Contract: ₹825 Cr international CDMO mandate now…
27-Oct-2026 13:45:19
• Revenue: Up 81% YoY to ₹755 Cr, supported by strong CDMO growth and improving business mix • EBITDA: Surged 273% YoY to ₹132 Cr, driven by higher operating l…
27-Oct-2026 13:34:02
REVENUE UP 81.38% AT ₹746.50 CR (YOY), UP 30.94% (QOQ) EBITDA UP 301.10% AT ₹123.12 CR (YOY), UP 49.17% (QOQ) MARGINS AT 16.49% VS 7.46% (YOY), 14.48% (QOQ)
28-Sept-2026 08:54:53
• First U.S. ANDA submitted for Sitagliptin Tablets USP in three strengths • Strengthens formulation, bioequivalence and regulatory dossier capabilities • Supp…
07-Sept-2026 08:50:46
• Installed reactor capacity for API and CDMO increased from 535 KL to 614 KL. • Capacity enhancement supports scale-up of commercial CDMO supplies and existin…
01-Jul-2026 08:45:34
• First dispatch valued at ~₹50 Cr completed in Q1FY2026-27, marking transition to commercial stage • Company expects to scale program further with additional…
30-Jun-2026 18:45:57
• Mr. Sanjay Suri's designation changed from Whole-time Director to Managing Director, effective July 1, 2026 • Appointment is for the balance tenure of his ex…